Phase 3 · Liraglutide

GRADE trial results

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study

Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication (years), Quarterly for 4 to 7 years. Glargine Insulin U-100: 1.3; Glimepiride: 1.3; Liraglutide: 1.5; Sitagliptin: 0.8.

Participants
7,850
Status
completed
Completed
2021-04-30
Sponsor
GRADE Study Group

As posted on ClinicalTrials.gov (NCT01794143), updated at source Feb 10, 2026. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Primary outcome

What GRADE measured first

Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medicationyears · Quarterly for 4 to 7 years · median
Glargine Insulin U-100n=1,263Glimepiriden=1,254Liraglutiden=1,262Sitagliptinn=1,268
1.3(0.6 to 2.5)1.3(0.6 to 2.3)1.5(0.6 to 2.7)0.8(0.5 to 2.0)
HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study MedicationParticipants · Quarterly, 4-7 years · count of participants
Glargine Insulin U-100n=1,263Glimepiriden=1,254Liraglutiden=1,262Sitagliptinn=1,268
852908860981
Secondary outcomes

What else it measured

Time to HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication.years · Quarterly, 4-6 years · median
Glargine Insulin U-100n=1,263Glimepiriden=1,254Liraglutiden=1,262Sitagliptinn=1,268
2.1(1.0 to 3.5)2.0(1.1 to 3.3)2.2(1.0 to 3.5)1.7(0.8 to 3.0)
HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication.Participants · Quarterly for 4 to 7 years · count of participants
Glargine Insulin U-100n=1,263Glimepiriden=1,254Liraglutiden=1,262Sitagliptinn=1,268
498633583697
The trial

How GRADE was run

The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.

  • Sulfonylurea (glimepiride): Sulfonylurea
  • DPP-4 inhibitor: DPP-4 inhibitor (sitagliptin)
  • GLP-1 receptor agonist: GLP-1 receptor agonist (liraglutide)
  • Insulin (glargine): Insulin (glargine), Lantus
Who could join the trial

Inclusion Criteria: 1. Men or women diagnosed with diabetes at age ≥ 30 years (≥ 20 for American Indians) 2. Duration of diagnosed diabetes \< 10 years 3. HbA1c criteria (at final run-in visit, \~2 weeks prior to randomization): 6.8-8.5% 4. Taking a daily dose of ≥ 1000 mg metformin for a minimum of 8 weeks at final run-in 5. Willingness to administer daily subcutaneous injections, take a second diabetes drug after randomization, potentially initiate insulin and intensify insulin therapy if study metabolic goals are not met, perform self-monitoring of blood glucose 6. Fluent in either English or Spanish 7. A negative pregnancy test for all females of childbearing potential (i.e. pre-menopausal, and not surgically sterile) 8. Provision of signed and dated informed consent prior to any study procedures Exclusion Criteria: 1. Suspected type 1 diabetes (lean with polyuria, polydipsia, and weight loss with little response to metformin) or "secondary" diabetes due to specific causes (e.g. previously diagnosed monogenic syndromes, pancreatic surgery, pancreatitis) 2. Current or previous (within past 6 months) treatment with any diabetes drug/glucose-lowering medication other than metformin (limited use of no longer than seven days is allowed, for example during hospitalization) 3. More than 10 years of treatment with metformin at time of randomization screening 4. History of intolerance or allergy or other contraindications to any of the proposed study medications 5. Resides in the same household with another GRADE study participant 6. Current need for any specific glucose-lowering medications solely for other conditions, for example for polycystic ovary syndrome 7. Symptomatic hyperglycemia requiring immediate therapy during screening or run-in, in the judgment of the physician 8. A life-threatening event within 30 days prior to screening or currently planned major surgery 9. Any major cardiovascular event in previous year, including history of myocardial infarction, stroke, or vascular procedure such as coronary artery or peripheral bypass grafting, stent placements (peripheral or coronary) or angioplasty. 10. Plans for pregnancy during the course of the study for women of child-bearing potential 11. History of or planning bariatric surgery, including banding procedures or surgical gastric and/or intestinal bypass (if banding removed, may be considered eligible after 1 year) 12. History of congestive heart failure (NYHA 3 or greater) 13. History of pancreatitis 14. History of cancer, other than non-melanoma skin cancer, that required therapy in the 5 years prior to randomization 15. Personal or family history of MEN-2 or family history of medullary thyroid cancer 16. Estimated GFR (eGFR) \<30 ml/min/1.73 m2 or end stage renal disease requiring renal replacement therapy 17. History of severe liver disease or acute hepatitis or ALT \> 3 times upper limit of normal 18. Current alcoholism or excessive alcohol intake 19. Previous organ transplant 20....

Published papers

Papers from GRADE

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.